Cargando…

Adjunctive immunomodulation in severe community-acquired pneumonia

Detalles Bibliográficos
Autores principales:	Bradley, James, Khurana, Shriya, Cavallazzi, Rodrigo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Pneumologia e Tisiologia 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578938/ https://www.ncbi.nlm.nih.gov/pubmed/37729338 http://dx.doi.org/10.36416/1806-3756/e20230248

Ejemplares similares

Pneumonia Severity Index and CURB-65 Score Are Good Predictors of Mortality in Hospitalized Patients With SARS-CoV-2 Community-Acquired Pneumonia
por: Bradley, James, et al.
Publicado: (2022)

Corticosteroids as Adjunctive Therapy in Severe Community-Acquired Pneumonia
por: Cillóniz, C., et al.
Publicado: (2016)

Advances in severe community-acquired pneumonia
por: Wang, Jian, et al.
Publicado: (2019)

Severity of community-acquired pneumonia treated with low-dose adjunctive corticosteroid
por: Mikami, Katsunaka, et al.
Publicado: (2011)

Adjunctive and Supportive Measures for Community-Acquired Pneumonia
por: Waterer, G. W., et al.
Publicado: (2010)

Contrasting Inflammatory Responses in Severe and Non-severe Community-acquired Pneumonia
por: Fernandez-Botran, Rafael, et al.
Publicado: (2014)

What’s new in severe community-acquired pneumonia? Corticosteroids as adjunctive treatment to antibiotics
por: Torres, Antoni, et al.
Publicado: (2015)

Adjunctive therapies and immunomodulating agents for severe influenza
por: Hui, David S. C., et al.
Publicado: (2013)

Severe community-acquired pneumonia: in search of the guiding star
por: Póvoa, Pedro, et al.
Publicado: (2023)

Viral infection in community-acquired pneumonia: a systematic review and meta-analysis
por: Burk, Michael, et al.
Publicado: (2016)

Association between body mass index and mortality in hospitalised patients with community-acquired pneumonia
por: Kim, Richard Y., et al.
Publicado: (2021)

Corticosteroids for severe community-acquired pneumonia: a story without an ending
por: Rochwerg, Bram
Publicado: (2022)

Community-Acquired Pneumonia in the Immunocompromised Host: Epidemiology and Outcomes
por: Ramirez, Julio A, et al.
Publicado: (2023)

In Patients Hospitalized for Community-Acquired Pneumonia, SARS-CoV-2 Is Associated with Worse Clinical Outcomes When Compared to Influenza
por: Spindel, Jeffrey, et al.
Publicado: (2023)

Severe community-acquired pneumonia
por: Morgan, AJ, et al.
Publicado: (2016)

Severe Community-Acquired Pneumonia
por: Khatib, Khalid, et al.
Publicado: (2019)

Severe Community-Acquired Pneumonia
por: Sligl, Wendy I., et al.
Publicado: (2013)

Severe community-acquired pneumonia
por: Niederman, Michael S., et al.
Publicado: (2022)

The role of biomarkers in community-acquired pneumonia: predicting mortality and response to adjunctive therapy
por: Mira, Jean-Paul, et al.
Publicado: (2008)

Adjunctive Corticotherapy for Community Acquired Pneumonia: A Systematic Review and Meta-Analysis
por: Marti, Christophe, et al.
Publicado: (2015)

Community-acquired pneumonia: challenges of the situation in Brazil
por: Gomes, Mauro
Publicado: (2018)

Community-Acquired Pneumonia
por: Rider, Ashley C., et al.
Publicado: (2018)

Cardiovascular Complications Are the Primary Drivers of Mortality in Hospitalized Patients With SARS-CoV-2 Community-Acquired Pneumonia
por: Ali, Ahmed Shebl, et al.
Publicado: (2023)

Changes in the epidemiology and burden of community-acquired pneumonia in Korea
por: Yoon, Hyoung Kyu
Publicado: (2014)

Corticosteroids for all adult patients with community-acquired pneumonia?
por: Spoorenberg, Simone M. C., et al.
Publicado: (2015)

Efficacy and Safety of Adjunctive Corticosteroids Therapy for Severe Community-Acquired Pneumonia in Adults: An Updated Systematic Review and Meta-Analysis
por: Bi, Jirui, et al.
Publicado: (2016)

Efficacy and safety of adjunctive corticosteroids therapy for patients with severe community-acquired pneumonia: A systematic review and meta-analysis
por: Huang, Jing, et al.
Publicado: (2019)

Antibiotic therapy, supportive treatment and management of immunomodulation-inflammation response in community acquired pneumonia: review of recommendations
por: Mantero, Marco, et al.
Publicado: (2017)

Ceftaroline in severe community-acquired pneumonia
por: Cilloniz, Catia, et al.
Publicado: (2022)

Steroids in severe community-acquired pneumonia: dangerous, worthless, or miracle cure? The roller coaster of clinical trials
por: Bouras, Marwan, et al.
Publicado: (2023)

Clinical outcomes in patients with COPD hospitalized with SARS-CoV-2 versus non- SARS-CoV-2 community-acquired pneumonia
por: Sheikh, Daniya, et al.
Publicado: (2022)

ICU admission and severity assessment in community-acquired pneumonia
por: Chalmers, James D
Publicado: (2009)

Community-acquired pneumonia: The need to broaden our diagnostic armamentarium
por: Perumal, R, et al.
Publicado: (2020)

Adjunctive intravenous then oral vitamin C for moderate and severe community-acquired pneumonia in hospitalized adults: feasibility of randomized controlled trial
por: Chambers, Stephen T., et al.
Publicado: (2023)

2110. Immunocompromised Adults Hospitalized with Community-Acquired Pneumonia in the United States: Incidence and Clinical Outcomes
por: Ramirez, Julio A, et al.
Publicado: (2022)

The host response in different aetiologies of community-acquired pneumonia: Potential new targets for adjunctive treatments?
por: Vestergaard Jensen, Andreas
Publicado: (2022)

Influenza and Viral Pneumonia
por: Cavallazzi, Rodrigo, et al.
Publicado: (2018)

Middle molecules in severe community-acquired pneumonia
por: Dumitras, T, et al.
Publicado: (2015)

Factors influencing severity of community-acquired pneumonia
por: Mahendra, M, et al.
Publicado: (2018)

PES Pathogens in Severe Community-Acquired Pneumonia
por: Cillóniz, Catia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_89vnl2qkv3i4log3io4j5n01b6